New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...
in.investing.com on MSN27m
Hims&Hers Health down as Citi downgrades on GLP-1 revenue stream overvaluationShares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback